Gemmer Asset Management’s AbbVie ABBV Stock Holding History

Gemmer Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$673K	Sell	2,676 -43	-2%	-$9.25K	0.05%	99
2026 Q1	$591K	Buy	2,719 +24	+0.9%	+$5.32K	0.05%	102
2025 Q4	$616K	Sell	2,695 -18	-0.7%	-$4.1K	0.05%	98
2025 Q3	$628K	Buy	2,713 +65	+2%	+$13.2K	0.05%	96
2025 Q2	$492K	Sell	2,648 -402	-13%	-$74.7K	0.04%	102
2025 Q1	$639K	Hold	3,050	–	–	0.06%	88
2024 Q4	$542K	Buy	3,050 +540	+22%	+$99.3K	0.05%	95
2024 Q3	$496K	Sell	2,510 -106	-4%	-$19.8K	0.05%	94
2024 Q2	$449K	Buy	2,616 +1	+0%	+$166	0.05%	90
2024 Q1	$476K	Sell	2,615 -71	-3%	-$12.2K	0.06%	83
2023 Q4	$416K	Buy	2,686 +55	+2%	+$8.02K	0.05%	82
2023 Q3	$392K	Sell	2,631 -336	-11%	-$49.3K	0.05%	79
2023 Q2	$400K	Sell	2,967 -1,345	-31%	-$197K	0.05%	77
2023 Q1	$687K	Buy	4,312 +161	+4%	+$24.6K	0.1%	58
2022 Q4	$671K	Buy	4,151 +115	+3%	+$17.6K	0.11%	57
2022 Q3	$542K	Buy	4,036 +15	+0.4%	+$2.15K	0.09%	66
2022 Q2	$616K	Buy	4,021 +18	+0.4%	+$2.75K	0.1%	66
2022 Q1	$648K	Sell	4,003 -16	-0.4%	-$2.32K	0.08%	71
2021 Q4	$544K	Buy	4,019 +281	+8%	+$33.2K	0.06%	81
2021 Q3	$403K	Sell	3,738 -158	-4%	-$18.1K	0.06%	84
2021 Q2	$439K	Buy	3,896 +43	+1%	+$4.84K	0.06%	86
2021 Q1	$417K	Buy	3,853 +1,569	+69%	+$168K	0.07%	83
2020 Q4	$245K	Sell	2,284 -97	-4%	-$9.32K	0.04%	89
2020 Q3	$209K	Hold	2,381	–	–	0.04%	89
2020 Q2	$234K	Sell	2,381 -55	-2%	-$4.84K	0.05%	87
2020 Q1	$186K	Buy	2,436 +173	+8%	+$14.7K	0.05%	85
2019 Q4	$200K	Sell	2,263 -73	-3%	-$6.06K	0.05%	86
2019 Q3	$177K	Buy	2,336 +97	+4%	+$6.65K	0.04%	90
2019 Q2	$163K	Sell	2,239 -1,488	-40%	-$117K	0.04%	96
2019 Q1	$300K	Sell	3,727 -10	-0.3%	-$818	0.08%	71
2018 Q4	$345K	Buy	3,737 +11	+0.3%	+$967	0.11%	66
2018 Q3	$352K	Sell	3,726 -317	-8%	-$30.1K	0.11%	64
2018 Q2	$375K	Hold	4,043	–	–	0.13%	60
2018 Q1	$383K	Sell	4,043 -100	-2%	-$11K	0.13%	60
2017 Q4	$401K	Buy	4,143 +200	+5%	+$18.8K	0.14%	62
2017 Q3	$350K	Hold	3,943	–	–	0.13%	63
2017 Q2	$286K	Hold	3,943	–	–	0.12%	68
2017 Q1	$257K	Hold	3,943	–	–	0.11%	68
2016 Q4	$247K	Sell	3,943 -4	-0.1%	-$244	0.12%	62
2016 Q3	$249K	Buy	3,947 +4	+0.1%	+$259	0.13%	57
2016 Q2	$244K	Hold	3,943	–	–	0.13%	57
2016 Q1	$225K	Buy	3,943 +4	+0.1%	+$223	0.13%	65
2015 Q4	$233K	Buy	3,939 +114	+3%	+$6.57K	0.14%	59
2015 Q3	$208K	Sell	3,825 -167	-4%	-$10.9K	0.13%	63
2015 Q2	$268K	Buy	3,992 +36	+0.9%	+$2.35K	0.16%	55
2015 Q1	$232K	Buy	3,956 +54	+1%	+$3.26K	0.14%	62
2014 Q4	$255K	Hold	3,902	–	–	0.17%	53
2014 Q3	$225K	Buy	3,902 +150	+4%	+$8.33K	0.16%	64
2014 Q2	$212K	Hold	3,752	–	–	0.14%	70
2014 Q1	$192K	Buy	+3,752	New	+$190K	0.14%	70

Other funds holding ABBV

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

HPC

HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

CRM

Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Gemmer Asset Management's ABBV Position: Q2 2026 in Review

Gemmer Asset Management reduced its AbbVie (ABBV) stake by 1.6% in Q2 2026, selling an estimated $9.25K and leaving 2,676 shares worth $673K. The position accounts for 0.05% of the portfolio, ranked #99.

Gemmer Asset Management first reported a position in ABBV in Q1 2014 and has held it in 50 quarters since. The position peaked at $687K in Q1 2023. 1,039 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Gemmer Asset Management held 2,676 shares of AbbVie worth $673K as of Q2 2026.
Gemmer Asset Management sold 43 AbbVie shares in Q2 2026, an estimated $9.25K.
AbbVie made up 0.05% of Gemmer Asset Management's portfolio in Q2 2026, its #99 holding.
Gemmer Asset Management first reported a position in AbbVie in Q1 2014 and has held it in 50 quarters since.
Gemmer Asset Management's AbbVie position peaked at $687K in Q1 2023.
1,039 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Gemmer Asset Management's 13F filing for Q2 2026, filed 15 Jul 2026.